Features for a bioscale that enable its role as a surrogate for a clinical end point beyond the NIH definition of a biomarker
| No. | Properties of a Bioscale | Implications |
|---|---|---|
| 1 | Image-derived map of the disease site | More sensitivity to earlier disease than diluted remote biomarkers |
| 2 | Spatially resolved quantitative parameter | Precise and accurate measurement |
| 3 | Small biologic variance in the healthy population | Sensitivity to early disease |
| 4 | Continuously and monotonically varying with disease progression | Sensitivity to disease progression or response to treatment |
| 5 | Intrinsically related to the disease mechanism | Highly conserved metabolic parameter, essential for use as a surrogate of a clinical end point |
Note:—NIH indicates National Institutes of Health.